Source link : https://www.newshealth.biz/health-news/another-possible-treatment-option-for-intermediate-stage-liver-cancer/
Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a targeted agent and immunotherapy were added to transarterial chemoembolization (TACE), initial results from a randomized trial showed. Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab (Keytruda). A subgroup analysis […]
Author : News Health
Publish date : 2024-09-16 17:15:02
Copyright for syndicated content belongs to the linked Source.
Categories